Ovid Therapeutics (OVID) Short-term Investments (2018 - 2026)

Ovid Therapeutics' Short-term Investments history runs 8 years deep, the most recent figure standing at $61.5 million for Q1 2026.

• Quarterly Short-term Investments rose 181.14% year-over-year to $61.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.5 million (up 181.14% YoY) and the FY2025 annual result came in at $56.5 million, up 110.96% from the prior year.
• Short-term Investments was $61.5 million for Q1 2026 at Ovid Therapeutics, up from $56.5 million in the prior quarter.
• Across five years, Short-term Investments topped out at $84.1 million in Q4 2022 and bottomed at $5.0 million in Q3 2025.
• A 5-year average of $48.0 million and a median of $51.2 million in 2023 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2025 — Short-term Investments tumbled 89.53% — and 2026, when it soared 181.14%.
• Ovid Therapeutics' Short-term Investments stood at $84.1 million in 2022, then slipped by 6.35% to $78.8 million in 2023, then plunged by 66.02% to $26.8 million in 2024, then surged by 110.96% to $56.5 million in 2025, then grew by 8.81% to $61.5 million in 2026.
• Business Quant data shows OVID's Short-term Investments at $61.5 million in Q1 2026, $56.5 million in Q4 2025, and $5.0 million in Q3 2025.